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Background: Status epilepticus (SE) may occur in the setting of several internal or neurologic diseases. Anti-neutrophilic
cytoplasmic antibodies (ANCA) are a group of Ig that may be observed in patients with different autoimmune disorders
but are particularly associated with systemic vasculitis named ANCA-associated-vasculities (AAV). We herein report 3
patients with SE and positivity to p-ANCA.
Case presentation: One patient had a catastrophic evolution and died 5 months after disease onset. The other
two patients had a good outcome and remained seizure-free at 30 months and 5 years of follow-up respectively.
Conclusion: This report highlights the importance of considering ANCA dosage in patients with SE of unclear origin.
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Status epilepticus (SE) may occur in the setting of sev-
eral neurologic or internal diseases. Anti-neutrophilic
cytoplasmic antibodies (ANCA) are a group of Ig that
may be observed in patients with different autoimmune
disorders but are particularly associated with systemic
vasculitis. ANCA-associated vasculitis (AAV) are rare
systemic autoimmune diseases affecting small to medium
sized blood vessels [1]. AAV include granulomatosis with
polyangiitis (formerly Wegener’s granulomatosis), micro-
scopic polyangiitis and eosinophilic granulomatosis with
polyangiitis (formerly Churg-Strauss syndrome). These con-
ditions may rapidly lead to multiple organ failure and death
if not early diagnosed [1]. AAV may involve different organs
especially upper and lower respiratory tracts, kidneys, skin.
Neurological manifestations are observed in about 20% of
patients, in particular peripheral neuropathy [1]. Seizures,
headache and stroke have rarely been reported in AAV
[2-7]. We herein report 3 patients presenting SE of unclear
origin, whose sera were positive for p-ANCA.* Correspondence: a.gambardella@unicz.it
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Patient 1
A 48-year-old man was diagnosed AAV with extracapil-
lary necrotizing glomerulonephritis confirmed by labora-
tory analyses and kidney biopsy. He was treated with a
single iv bolus of cyclophosphamide 5 mg and iv methyl-
prednisolone 250 mg/day for 3 days, followed by oral
prednisone 1 mg/kg/day. Two months later he was admit-
ted because of generalized convulsive SE treated with iv
bolus of lorazepam 4 mg. Post-ictal neurological examin-
ation showed no deficits. Neither skin lesions nor involve-
ment of joints were evident. Brain MRI (Figure 1A) showed
small-sized hyperintense T2- and FLAIR-weighted lesions
in periventricular and subcortical white matter without
contrast enhancement. A vast haematological screening
was normal and included haemachrome, liver function,
electrolytes, coagulation, angiotensin-converting en-
zyme, microbiological tests for hepatitis, toxoplasma,
rubella, CMV, HSV 1 and 2, syphilis, ferritin, immuno-
globulin dosage, antinuclear antibodies (ANA), extractable
nuclear antibody (ENA) including anti-dsDNA, anti-Ro/
SSA, anti-La/SSB, anti-histone, anti-nRNP, anti-Jo-1,
anti-Scl70, anti-Sm, c-ANCA, rheumatoid factor, C3, C4,
lupus anticoagulant (LAC), anti-thyroid antibodies, alpha-
fetoprotein, carcino-embryonic antigen, neuronal-specific
enolase, prostatic-specific antigen, CA19-9. Abnormal re-
sults were serum creatinine 7.82 mg/dl (not worsened asl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Brain MRI in our series. A (patient 1, at entry): hyperintense spots in axial FLAIR sequence involving periventicular and subcortical
white matter. B, C (patient 1, one month later): axial FLAIR sequence showing multiple cortico-subcortical hyperintense lesions, some of which
enhanced after gadolinium administration (axial T1: C). No meningeal enhancement is observed. D, E (patient 2, at entry): multiple nodular
cortico-subcortical FLAIR hyperintense lesions involving fronto-temporal and insular regions. F (patient 2, three years later): axial FLAIR sequence revealing
no abnormality. G (patient 3, three years after disease onset): axial FLAIR sequence showing a vast hyperintense cortico-subcortical temporo-occipital lesion.
H, I (patient 3, two years after treatment onset with azathioprine): axial T1 revealing mild cortico-subcortical atrophy involving right temporal and occipital
lobes with dilatation of posterior horn of right lateral ventricle. Magnification of right posterior atrophy by axial IR (I).
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protein 102 mg/l, positivity to p-ANCA (as detected by
both indirect immunofluorescence and ELISA for ANCA-
MPO), microhaematuria. CSF analysis, including cultures,
was negative. Chest CT scan revealed interstitial lung
disease. Spirometry showed mild restrictive ventilatory de-
fect. Electrocardiography, echocardiography and abdominal
MRI were normal. He was treated with iv methylpredniso-
lone 1 gr /day for 5 days and was discharged with carba-
mazepine 400 mg/day and prednisone 1 mg/kg/day. Onemonth later, he was again admitted because of sudden con-
fusional state with hematemesis, haemoptysis, nosebleed
and macroscopic haematuria. Blood pressure was normal.
Haematological examination showed severe anaemia and
multiple organ (kidney, pancreas, liver) failure. CSF analysis
revealed high protein level (417 md/dl; n.v. 18–43).
Polygraphic recording revealed asterixis, slow back-
ground activity and bilateral triphasic waves. Brain
MRI showed multiple cortico-subcortical lesions, some
of which enhanced after gadolinium administration
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3 days after admission, 5 months after disease onset.
Patient 2
A 44-year-old coeliac man presented with fever, lymph-
adenopathy and haemolytic anaemia of unknown origin,
treated with prednisone 1 mg/kg/day. In the same epoch
he presented weekly short-lasting episodes of epigastric
aura with sweating and was prescribed levetiracetam 1
gr/day. Two months later he was admitted for refractory
SE with left hemibody clonic jerks not responding to i.v.
boli of lorazepam 4 mg and phenytoin 20 mg/kg. Neuro-
logical examination was otherwise normal. He was given
oral levetiracetam 2 gr/day and topiramate 200 mg/day,
but clonic jerks persisted. EEG showed periodic latera-
lized epileptic activity over right fronto-centro-temporal
regions. Neither skin lesions nor joints involvement
joints were evident. Brain MRI showed multiple lesions
involving cortico-subcortical fronto-temporal regions
(Figure 1D, E) without contrast enhancement. The same
laboratory panel as patient 1 was unremarkable except
for ANA 1:320 (speckled pattern as detected by indirect
fluorescence antibody test), ESR 24 mm/h, C reactive
protein 257 mg/l, positivity to p-ANCA (as detected
by both indirect immunofluorescence and ELISA for
ANCA-MPO). Urinalyses, including microalbuminuria,
and serum creatinine were normal. CSF analysis showed
oligoclonal bands; cultures were negative. Abdominal
and pelvic CT scans, electrocardiography and echocar-
diography were normal. Methylprednisolone 1 gr/day
was administered for 5 days. He was then given i.v.
rituximab (600 mg/week for 4 weeks). During the
following 5-year follow-up he had no relapses and remainedFigure 2 EEG showing recruiting, fast “tonic” activity over right poste
followed by sharp theta activity over ipsilateral temporo-occipital lea
placed according to the International 10–20 system). The trace is compressseizure-free with levetiracetam 2 gr/day. A control MRI
performed 3 years later was normal (Figure 1F).
Patient 3
A previously healthy 17-year-old girl started presenting
long-lasting episodes of vision of colored circles,
followed by headache. At age 18 she developed almost
continuous short-lasting episodes of sensation that “eyes
move like windscreen wiper”. A brain MRI performed at
that time revealed a vast hyperintense lesion in T2,
FLAIR and diffusion-weight images, involving the right
temporo-occipital lobes. Muscle biopsy was normal and
genetic test to detect MELAS mtDNA mutations was unre-
markable. Molecular screening (direct sequence analysis
and multiplex ligation-dependent probe amplification) of
DNA polymerase subunit gamma-1 (POLG1) was normal.
Treatment with topiramate 200 mg/day was started and
she remained asymptomatic over 2 years. Thereafter, topir-
amate had to be discontinued due to side effects and carba-
mazepine up to 800 mg/day was given. Several brain MRI
performed 6, 12 and 24 months later were normal. After-
wards, she was admitted for blurred vision and frequent
short-lasting sensations that “eyes move like windscreen
wiper”. EEG (Figure 2) disclosed recurrent occipital seizures
every 3–10 minutes clinically characterized by horizontal
nystagmus towards the left. Neurological examination re-
vealed left lower homonymous quadrantanopia. SE stopped
after i.v. bolus of diazepam 10 mg. Neither skin lesions nor
involvement of joints were evident. Brain MRI showed a
well-defined right temporo-occipital lesion (Figure 1G)
without contrast enhancement. The same haematological
screening as patients 1 and 2, revealed ANA 1:320
(speckled pattern as detected by indirect fluorescencerior head regions, predominant over right occipital lead (O2),
ds. Seizure lasts about 75 seconds (bipolar montage, scalp electrodes
ed to show seizure in its all duration.
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by both indirect immunofluorescence and ELISA for
both ANCA-MPO and ANCA-PR3). Moreover, C re-
active protein and the erythrocyte sedimentation rate
were elevated. Tests for coeliac disease, syphilis, Lyme
disease, anti-glutamate receptor (2 and 3) antibodies
and paraneoplastic antibodies were negative. CSF analysis,
including cultures, was normal. Urinalyses, including
microalbuminuria, were normal. Electroneuromyography,
electrocardiography, chest X-ray, abdominal and pelvic
ultrasound were unremarkable. She was given carbamaze-
pine 800 mg/day. In the following 14 months, two similar
episodes of occipital SE associated with transitory MRI ab-
normalities recurred and resolved with appropriate antiep-
ileptic therapy. After the last SE, brain MRI revealed right
temporo-parieto-occipital atrophy (Figures 1H, I). Due to
the persistence of positive p-ANCA and ANA, she was
given carbamazepine 800 mg/day, oral prednisone 50 mg/
day for one month, followed by azathioprine 75 mg/day,
remaining seizure-free during 30-month follow-up.
The right temporo-parietal-occipital atrophy remained
unchanged in control MRI.
Conclusions
In our series, SE represented the main or first neuro-
logical manifestation. Although the presence of a CNS
vasculitis was not confirmed by brain biopsy or angiog-
raphy, positivity to p-ANCA prompted us to suspect an
autoimmune aetiology and to begin immunotherapy.
Moreover, the proposed diagnostic criteria of AAV are
based on systemic symptoms and signs, serological,
radiological or histological findings, exclusion of other
conditions as malignancy, infections, drugs, sarcoidosis,
secondary vasculitis [8]. Patient #1 fulfilled the diagnos-
tic criteria for AAV [8] with central nervous system
(CNS) involvement. Indeed, he had positivity for p-ANCA
along with systemic signs of disease (glomerulonephritis
and pulmonary interstitiopathy), histological proof of vas-
culitis and no other diagnosis accounting for the clinical
picture. MRI picture could suggest a “posterior reversible
encephalopathy syndrome or PRES [9]. However, contrast
enhancement at MRI, normality of blood pressure, and ab-
sence of worsening of kidney function during SE, does not
support this hypothesis. Patient 2 also had positivity of p-
ANCA, in the presence of non-specific signs of vasculitis
(fever, lymphadenopathy and haemolytic anaemia) along
with absence of other diagnosis accounting for the clinical
picture, thus fulfilling only 2 out of 3 necessary criteria.
However, the positivity of p-ANCA prompted us to start
treatment with rituximab with good outcome. Patient 3 also
fulfilled 2 out of 3 proposed criteria for AAV (positivity for
p-ANCA and exclusion for other conditions accounting for
her symptoms, including the above-mentioned diseases).
An atypical form of Rasmussen encephalitis could besuggested in this patient [10]. However, the clinical findings
as well as the extensive laboratory investigation, including
the MRI features (with no characteristic evolutional
changes of MRI occurring at long-term follow-up, includ-
ing the atrophy of the head of the caudate nucleus) made
this diagnosis very unlikely. Therefore, all these data, along
with the prompt response to azathioprine treatment,
strongly suggested the diagnosis of an autoimmune
disorder with p-ANCA positivity limited to CNS in this
young patient. Of interest, in the same patient, we also
excluded genetic conditions potentially leading to focal
brain lesions and seizure disorder, including POLG
mutations. Indeed, it is known that POLG mutations
may cause a progressive neurological disorder usually
starting in teens with occipital lobe epilepsy and fre-
quent SE [11]. This observation suggests that AAV
should be considered in the differential diagnosis with
POLG mutations in patients presenting with occipital
seizures or SE.
A study [12] on natural history of AAV found that aver-
age patient survival is about five months and more than
90% of patients die within two years. Standard treatment of
AAV usually consists of inducing remissions with high dose
steroids or cyclophosphamide, and maintaining remission
with immunosuppressants. New therapeutic agents include
rituximab, a monoclonal antibody depleting B cell, ap-
proved by FDA in US for use in AAV. The striking and
long-lasting response in patient 2 confirms that rituximab
may represent a therapeutic alternative to classic immuno-
suppressant for AAV in some patients. Patient 3 too had a
good outcome and remained seizure-free at follow-up with
immunosuppressant and antiepileptic treatment. On the
contrary, patient 1 had extremely rapid and fatal evolution
due to small vessel necrotizing vasculitis and multiple
organs bleeding despite treatment with steroids.
The exact nature of cortico-subcortical hyperintensities
associated with SE remains elusive, even if such changes
may be at least in part related to cytotoxic edema [13].
Regardless the pathophysiological mechanism, we believe
that the present series strengthens the view that both SE
and brain hyperintensities should be targets of rational
treatment, as there is now agreement that SE and its com-
bination with sterile brain inflammation are the major
determinants of sequelae [14]. In this way, it may be ques-
tioned if an earlier immunosuppressive treatment in our
patient #3 could have prevented the irreversible loss of
brain parenchyma.
In conclusion, physicians should consider ANCA dos-
age in patients presenting with otherwise unexplained
SE or seizures, inflammatory changes at brain MRI, with
or without other systemic signs or symptoms of AAV.
Indeed, in this peculiar clinical setting, ANCA positivity
may lead physicians to suspect an autoimmune aetiology
and to promptly start adequate immunotherapy.
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